Article
Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Clinical Cancer Research, a journal of the American Association for Cancer Research, will publish results today from the COSMOS study confirming the high sensitivity and specificity of the Guardant Reveal blood test in predicting recurrence…
Read MoreExcerpt from the Press Release: CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) — August 7, 2024: Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the first patient has been dosed in the Phase 1 clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of…
Read More– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end – Based on the modeling and simulations, Palisade has established dose levels and trial design for PALI-2108 Excerpt from the Press Release: Carlsbad, CA, Aug. 08, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI)…
Read More– Preclinical data suggest combination of ziftomenib and imatinib has potential to resensitize patients to imatinib and induce durable responses – – Proof-of-concept study evaluating ziftomenib and imatinib in patients with advanced GIST to begin in 1H 2025 – Excerpt from the Press Release: SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc.…
Read MoreCompany announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support the development of the Company’s two clinical-stage T cell engaging assets to treat solid tumors Excerpt from the Press Release: PHILADELPHIA, Aug. 01, 2024 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:…
Read MoreExcerpt from the Press Release: LOWELL, Mass., July 31, 2024 /PRNewswire/ — Alcyone Therapeutics Inc. (Alcyone), a clinical-stage biotechnology company pioneering next-generation precision genetic therapies and precision delivery solutions of therapies for complex neurological conditions, announced today that the U.S. Food and Drug Administration (FDA) has provided approval to continue enrollment of the PIERRE study (https://clinicaltrials.gov/ct2/show/NCT05866419) to…
Read MoreExcerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced encouraging preclinical data on PIPE-307,a potentially first-in-class M1…
Read MoreNew Research shows promising, sustained results for personalized treatment of treatment-resistant depression Excerpt from the Press Release: BURLINGAME, Calif.–(BUSINESS WIRE)–Magnus Medical, Inc., a pioneering therapeutic neuromodulation company transforming the treatment of neuropsychiatric disorders, today announced promising new clinical data on SAINT® therapy at the 2024 NYC Neuromodulation Conference, Aug 1-3. The research will be presented…
Read MoreExcerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced topline data from its Phase 2 ASPEN-06 clinical trial. The trial demonstrated clinically meaningful improvements…
Read MoreAgency feedback from Type C meeting process supports the company’s proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Plan to initiate dosing of FTD-C9orf72 patients in 1H 2025 Excerpt from the Press Release: PHILADELPHIA, July 16, 2024 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ:…
Read More